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Abstract 
Readmissions of heart failure (HF) patients are a costly and potentially avoidable 
expenditure for our healthcare systems. In 2015, acute care facilities who exceed pre-
determined benchmarks for 30-day HF readmission rates set by the Centers for Medicare 
and Medicaid Services (CMS) will see substantial penalties resulting in reductions in all 
Medicare reimbursement (Centers for Medicare and Medicaid Services [CMS], 2014). In 
an attempt to mitigate the financial burden associated with heart failure 30-day 
readmission rates, new techniques must be developed to identify the risk factors associated 
with this condition.  The risk-standardized readmission rates (RSRRs) for heart failure 
have decreased from 23.4 % in July 2010 to 21.9% in June 2013 (CMS, 2013). Despite 
this decline, reducing readmission rates is a national priority in an effort to reduce rising 
healthcare costs (CMS, 2014). The purpose of this project was to identify trends of 30-day 
heart failure readmissions and evaluate the efficacy and feasibility of a discharge risk 
assessment implemented to stratify those at highest risk for 30-day readmission for heart 
failure. This discharge risk assessment for readmission was implemented at a North 
Carolina rural community hospital and targets an acute care population with a 30-day 
readmission rate higher than the current national median. The project design was a 
retrospective data analysis of all patients readmitted to the hospital within the first 30-days 
post discharge for treatment of heart failure as a primary diagnosis.  Rogers’ Diffusion of 
Innovation provided the theoretical foundation for the project. Results of the retrospective 
chart review showed that neither age, nor time of follow up visits, nor medication 
regimens were predicting factors of 30-day heart failure readmissions.  Heart failure 30-
day readmissions are due to multiple factors.  The prediction and prevention of 30-day 
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heart failure readmissions requires an interprofessional approach to create robust strategies 
to address this issue. 
Keywords: heart failure, 30-day readmission, prevention, prediction 
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CHAPTER 1: INTRODUCTION 
The Center for Disease Control and Prevention (CDC) estimates that five million 
people in the US are diagnosed with heart failure (HF) each year (CDC, 2013).  The CDC 
estimates that HF costs the United States 32 billion dollars per year. One half of HF 
patients die within 5 years of initial diagnosis (CDC, 2013).  An estimated 20% of HF 
Medicare beneficiaries are readmitted within 30 days of discharge (Medicare Payment 
Advisory Commission [MedPAC], 2007). Readmissions are costly and potentially 
avoidable.  The risk-standardized readmission rates (RSRRs) for HF have decreased from 
23.4 % in July 2010 to 21.9% in June 2013 (CMS, 2013). Despite this decline, reducing 
readmission rates is a national priority.  
In 2015, acute care facilities who exceed CMS pre-determined benchmarks for 30-
day HF readmission rates set by CMS will lose up to 3% of Medicare reimbursement 
(CMS, 2014). In order to mitigate the financial burden associated with HF 30-day 
readmission rates, new techniques must be developed to identify the risk factors associated 
with HF readmissions and create strategies to prevent their occurrence.   
Statement of Purpose 
The purpose of this project was to 1) identify causes for 30-day heart failure 
readmissions in a rural community hospital, 2) identify trends of readmission predictors in 
order to stratify those at highest risk for 30-day readmissions, and 3) suggest strategies to 
reduce 30-day HF readmissions for the most common cause of readmissions. The project 
was implemented in a North Carolina rural community hospital that targeted an acute care 
population whose rate of heart failure 30-day readmission is higher than the current 
national median. 
30-DAY HEART FAILURE READMISSIONS 
 
10 
Background of the Problem 
Heart failure is a complex clinical syndrome resulting from functional or structural 
impairment of the cardiac pump.  Classic symptoms include shortness of breath, fatigue, 
and ankle swelling. Classic signs include elevated jugular vein distention, pulmonary 
crackles, and displaced apical pulse (McMurray et al., 2012). Evidence shows diagnosis in 
the elderly is challenging due to existing co-morbidities and atypical symptomology 
(Oudejans et al., 2011). In order to classify the severity of HF patients, providers use either 
the American College of Cardiology /American Heart Association (ACC/AHA) stages, 
based on structural changes and clinical presentation, or the New York Heart Association 
(NYHA) classification system, based on symptom related functional debility (American 
Heart Association, 2015).  The ACC/AHA stages determine the progression of the disease; 
whereas, the NYHA functional classification emphasizes the activity level and associated 
severity of symptoms (American Heart Association, 2015).  
The prevalence of individuals with HF is an estimated 5 million people ≥ 20 years 
old (Go et al., 2013).  The prevalence of HF is expected to increase by 46% resulting in 
greater than 8 million people ≥ 18 years old who are diagnosed with HF by 2030 (Go et al., 
2013).  The incidence of HF is 825,000 new cases annually (American Heart Association, 
2015).  According to the American Heart Association (2015), HF incidence approaches 
10/1000 after 65 years of age. Between the ages of 60-79, 7.8% of men and 4.5% of 
women are diagnosed with HF.  After 80 years old, 8.6% of men and 11.5% of women are 
diagnosed with HF (American Heart Association, 2015). The current cost of treating HF is 
30 million dollars per year.  However, the projected cost by 2030 is estimated at 69.7 
billion dollars per year, an increase of 127% (Go et al., 2013; Godfrey et al., 2013).  
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The national readmission rate for Medicare HF patients averages 24.7% with direct and 
indirect costs of $37.2 billion annually (Godfrey et al., 2013). Since the introduction of the 
Patient Protection Affordable Care Act in 2010, a national priority has been to reduce 
hospital readmissions in order to reduce healthcare costs (CMS, 2013). In 2012, CMS 
initiated the Readmission Reduction Program.  However, RSRRs for heart failure have 
only decreased by 1.5% over a three-year period extending from 2010 to 2013 (CMS, 
2013). The purpose in implementing this program was to reduce payments to inpatient 
prospective payment system hospitals with excessive readmissions. Hospitals across the 
country are continuing to be faced with the challenge of reducing readmissions rates for 
heart failure patients.  
Significance of the Problem 
The etiology of HF 30-day readmissions is as diverse as the patients who suffer 
from the disease. Advanced Practice Registered Nurses (APRNs) must ascertain the 
etiology of 30-day HF readmissions in order to develop strategies to prevent their 
occurrence. APRNs must ameliorate processes to ensure seamless care between the 
hospital and community.  A multidisciplinary approach including optimal medical 
treatment, adequate follow up, access to healthcare, patient education, and psychological 
support must be in place to improve the quality of life for HF patients and reduce 30-day 
readmissions (Black, 2014).   
Identifying HF patients at high risk for readmission provides essential information 
to develop target strategies and maximize outcomes. Prediction models have been created 
to stratify patients at risk.  However, efforts to date have yielded inconsistent findings and 
no prediction model has been universally accepted as the gold standard. A study of 
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2,536,439 HF hospitalizations conducted by Aggarwal and Gupta (2014) revealed that 30-
day HF readmissions were attributed to varying demographic parameters such as age, payer 
source, and/or gender.  They suggested that strategies tailored to specific causes for certain 
populations need to be implemented to reduce 30-day HF readmissions (Aggarwal & 
Gupta, 2014). 
Practice Setting 
This scholarly project was conducted in a rural 280-bed, county owned, not-for-
profit acute care facility. The facility employs 1500 people and serves two counties.  In 
2014, the facility reported a $17 million deficit, partly due to Medicare penalties attributed 
to 30-day readmissions.  In order to offset the deficit, the stakeholders invested in a 
readmission predictor tool in order to prevent future penalties.   
CHAPTER 2: RESEARCH BASED EVIDENCE 
Synthesis of Evidence 
A comprehensive review of the literature was conducted using the key words: 
heart failure, 30-day readmission, readmission prevention, and prediction model. PubMed, 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), and ProQuest 
Nursing and Allied Health Source databases were searched. Inclusion criteria was articles 
from the past five years, those written in English, peer review journals consisting of 
randomized control trials, systematic reviews, meta analyses, and clinical practice 
guidelines. Hand searches of reference lists were completed to identify additional 
resources. Exclusion criteria included duplicate articles and articles that did not address 
solutions to 30-day heart failure readmissions.  
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The initial literature search for heart failure resulted in more than 35,000 articles.  
Thirty-day heart failure readmission literature search produced 3876 articles.  Thirty-day 
heart failure readmission causes, prevention and prediction model resulted in 185 articles.  
The abstracts of these articles were reviewed.  For the purpose of this scholarly project, 50 
articles including clinical guidelines were chosen as pertinent to the objective of identifying 
trends and readmission prevention strategies.  
The literature review included four main categories including heart failure, 30-day 
heart failure readmissions, heart failure readmission prediction models, and heart failure 
readmission prevention strategies. 
Heart Failure 
The European Society of Cardiology (ESC) guidelines for the diagnosis and 
treatment of acute and chronic heart failure and the American College of Cardiology 
Foundation (ACCF)/American Heart Association (AHA) guidelines for the management of 
heart failure provided evidence-based guidelines (McMurray et al., 2012; Yancy et al., 
2013). Both of these guidelines used findings from numerous randomized controlled trials 
with the highest level of evidence to develop the guidelines.  The clinical evidence for 
medication management for HF patients from these guidelines was incorporated in the 
chart review tool utilized in this scholarly project.  
Thirty-Day HF Readmissions 
Understanding 30-day readmission trends discussed in the literature increases the 
likelihood of implementing target interventions (Eastwood et al., 2014).  Schell stated, “the 
etiology of hospital readmissions for HF is as diverse as individuals who have the disease” 
(2014, p. 232).  A literature review conducted by Giamouzis et al. (2011) stated that several 
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studies associate HF 30-day readmissions with increased age, non-white race, lower 
socioeconomic status, increased cardiac ischemia, and presence of comorbidities.   
 Eastwood et al. (2014) studied 18,590 patients who were readmitted between seven and 30 
days after hospitalization.  Logistic regression was used in their study to identify factors 
contributing to readmissions. The study identified the following contributing factors for 
readmission:  1) readmission that included discharge with the need for additional home 
health services, 2) discharged against medical advice, 3) kidney disease and 4) discharged 
from hospitals without specialized HF services. Limitations of the study included failure of 
notation of medication history, documented severity of cardiac disease and uncertainty if 
patients followed up post discharge. 
Sherer, Crane, Abel, and Efird (2014) conducted a retrospective cohort study of 
245 HF inpatients to examine the effects of socio-demographic and clinical factors on HF 
readmissions. Using Cox regression, the results suggested that the number and type of 
comorbidities including renal insufficiency, atrial fibrillation, cardiomyopathy, and history 
of myocardial/infarction were predictors of HF readmissions. The authors concluded that 
knowledge of certain comorbidities identified in this study could help target those patients 
at higher risk for readmission. Limitations of the study were uncertainty of accurate 
recording of the data and missing data in the reviewed charts. 
Readmission Prediction Models 
Prediction models for readmission are complex due to the myriad of unique 
clinical data, administrative data, and social factors of each patient (Aggarwal and Gupta, 
2014; Amarasingham et al., 2010). Reed, Bokovoy, and Doram (2013) investigated five 
logistic regression models for 30-day readmission after HF hospitalizations based on 
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administrative data including the CMS Readmission Model, the LACE Index, the Hanson 
Score, the PARR score, and the AH Model.  The results of their study showed the Hansan, 
PARR, and AH Model were the strongest predictors of unplanned 30-day HF readmissions. 
Au et al. (2012) concluded that none of the administrative database models were 
sufficiently accurate to predict HF 30-day readmission.  However, Au et al. (2012) stated 
that the LACE Index is superior to other CMS models for risk of death or readmissions 
since it incorporates length of hospital stay.  
Hebert et al. (2014) performed a retrospective cohort study in order to create a 
readmission risk model through their electronic health record.  They developed 
readmission-risk models for acute myocardial infarction, pneumonia, and congestive heart 
failure.  The congestive heart failure readmission-risk model performed poorly due to 
emphasis on social and behavioral variables in the chronic heart failure patients, thus 
complicating the ability to predict heart failure readmissions. 
Readmission Prevention Strategies   
Strategies implemented to address 30-day HF readmissions were heavily cited.  
Bradley et al., (2013) used a linear regression model to determine readmission prevention 
strategies.  According to their findings, the following were associated with lower RSRRs: 
1) partnering with community physicians, 2) partner with local hospitals, 3) nurses 
responsible for medication reconciliation, 4) follow-up appointments made before 
discharge, 5) seamless process to have inpatient medical records transferred to primary 
care provider, and 6) assign staff to follow up on test results that are available after the 
patient is discharged. Delgado-Passler and McCaffrey (2006) determined through their 
literature review that APRN directed heart failure post discharge management reduces 
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readmissions.  A study conducted by David, Britting, and Dalton (2014) went further to 
state patients receiving care from a medical team that included APRNs were 50% less 
often to be readmitted.  
A new initiative introduced by the American College of Cardiology (ACC) known 
as the Patient Navigator program is aimed at preventing heart failure readmissions (Schell, 
2014). The ACC recruits hospitals that already participate in the Hospital to Home 
Initiative and provides a team to assist patients in the challenges of heart failure 
management post discharge when they are most vulnerable (Schell, 2014). 
Definitions and Concepts 
Heart Failure 
Heart failure is a complex clinical syndrome defined as impairment of the systolic 
ventricular filling and ejection of blood by the cardiac pump to deliver oxygen to meet 
metabolic requirements (Yancy et al., 2013; McMurray et al., 2012).  An overview of the 
different types of heart failure follows including left ventricle failure, right ventricle failure, 
systolic heart failure, and diastolic heart failure. 
Left ventricle failure. Left ventricle failure is defined as a dysfunction of the 
contractile function of the left ventricle, resulting in a low cardiac output (Urden, Stacy & 
Lough, 2014). This leads to vasoconstriction of the arterial bed that raises systemic 
vascular resistance. The increased resistance creates congestion and edema in the 
pulmonary circulation and alveoli (Urden et al., 2014). Patients presenting with left 
ventricular failure may present with decreased exercise tolerance or fluid retention (Urden 
et al., 2014).  Over time the increased pulmonary congestion and edema can lead to right 
ventricle dysfunction.  
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Right ventricle failure.  Right ventricle failure is defined as the dysfunction of the 
contractile function of the right ventricle (Urden et al., 2014). Associated symptoms of 
right ventricular failure include jugular venous distention, weakness, peripheral or sacral 
edema, hepatomegaly, jaundice, and liver tenderness. Gastrointestinal symptoms include 
poor appetite, anorexia, nausea, and an uncomfortable feeling of fullness (Urden et al., 
2014).  
Systolic heart failure.  Systolic heart failure is defined as the marked decrease 
of contractility of the heart muscle during systole, resulting in low cardiac output and 
ejection fraction below 50% (Urden et al., 2014). Associated symptoms of systolic heart 
failure include dyspnea, exercise intolerance, and fluid volume overload.  As systolic 
dysfunction progresses, the left ventricular end-diastolic pressure rises.  The blood flowing 
through the pulmonary vascular bed meets resistance against the congested heart, 
therefore causing a backup of fluid and pressure. The fluid ultimately leaks through the 
walls of the alveoli causing pulmonary edema (Urden et al., 2014). . Elevated left heart 
pressures lead eventually to right heart pressure.  
Diastolic heart failure.  Diastolic heart failure is defined as the inability of the 
heart muscle to relax, stretch or fill during diastole (Urden et al., 2014). Cardiac muscle 
and cardiovascular vessels stiffen during the aging process causing impaired relaxation 
(Urden et al., 2014).  Associated symptoms include exercise intolerance, dyspnea, fatigue, 
and pulmonary edema (Urden et al., 2014). Studies have shown that patients with diastolic 
heart failure have a preserved ejection fraction defined as 45% or greater. An ejection 
fraction above the range of 40% to 50% is considered normal for this population (Urden et 
al., 2014). 
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Ejection Fraction 
     Ejection fraction (EF) is defined as the ratio of the volume of blood emptied 
during systole to the volume of blood that remains in the heart at the end of diastole and is 
the measurement of left ventricular function (Ejection Fraction, 2014).   Heart failure with 
an EF ≤ 40% is referred to as HF with a reduced EF (HFrEF), historically known as 
systolic HF.  Heart failure with an EF ≥ 40% is referred to as HF with a preserved EF 
(HFpEF), historically known as diastolic HF (McMurray et al., 2012).  The majority of 
randomized control trials to determine treatment modalities for HF have only studied 
HFrEF and the treatment modalities have proven efficacious in only this group to date 
(Yancy et al., 2013). 
Echocardiogram 
Although a clinical diagnosis, doppler echocardiography assists the clinician in 
identifying the cause and type of heart failure is made using (Urden et al., 2014). Doppler 
flow studies coupled with ultrasound determine whether abnormalities of the myocardium, 
heart valves, or pericardium are present and which chambers are involved in heart failure. 
  
E/A Ratio 
  Two waves are seen during echocardiogram with measures recorded during flow 
across the mitral valve (Ashley & Niebauer, 2004).  The early (E) wave represents passive 
filling of the ventricle.  The atrial (A) wave represents active filling during atrial systole.  
In a healthy heart, the E-wave velocity is slightly greater than that of the A-wave. 
However, in diastolic heart failure a reversal is noted in which the A wave is greater than 
the E wave. This indicates impaired relaxation and slow filling, known as E/A reversal 
30-DAY HEART FAILURE READMISSIONS 
 
19 
(Ashley & Niebauer, 2004). 
Pulmonary Hypertension 
The Pulmonary Hypertension Association defines pulmonary hypertension as an 
increased pressure in the lungs (2015). The World Health Organization (WHO) first 
defined classifications of pulmonary hypertension in 1973 (Pulmonary Hypertension 
Association, 2015). Pulmonary hypertension due to left sided heart failure is classified as 
Group 2.  WHO Group 2 pulmonary hypertension is defined as mean pulmonary artery 
pressure (mPAP) ≥ 25 mm Hg and left ventricular (LV) filling pressure ≥ 15 mmHg. 
Diastolic heart failure is frequently the cause of pulmonary hypertension (Pulmonary 
Hypertension Association, 2015). 
30-day Readmission 
 Patients identified with ICD-9 heart failure codes returning to the hospital ≤ 30 
days from date of discharge (CMS, 2015).  
Medication management 
Although there are numerous evidence-based pharmacological agents utilized in the 
management of heart failure, this author will concentrate on three medications considered 
to be key agents in the management of heart failure and considered to be benchmarks for 
standard care for heart failure management within the acute care setting. 
Beta-antagonists (beta-blockers). Beta antagonists is defined as a class of drugs 
that counteract the sympathetic nervous system and Renin-Angiotensin-Aldosterone-
System (RAAS), which decreases preload and afterload and inhibits ventricular 
remodeling (Maron & Rocco, 2011).  A meta-analysis involving 22 trials and over 10,000 
patients concluded that beta-blocker therapy is associated with clinically meaningful 
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reduction in mortality and morbidity (Brophy & Rouleau, 2001).  Three randomized 
controlled trials including Cardiac Insufficiency Bisoprolol Study II (CIBISII), Carvedilol 
Prospective Randomized Cumulative Survival (COPERNICUS), and Metoprolol 
controlled release/extended release Randomized Intervention Trial in Congestive Heart 
Failure (MERIT-HF) showed that beta-blocker therapy reduced mortality by 34% and 
hospitalization by 28-36% within one year of initiation of therapy (McMurray et al., 
2012). The beta-blockers shown to reduce morbidity and mortality include bisoprolol, 
carvedilol, and metoprolol (Maron & Rocco, 2011).  Bisprolol and Metoprolol are 
cardioselective beta-blockers that have a greater affinity for beta1-adrenergic receptors.  
Carvedilol has a greater affinity for beta1-adrenergic receptors, beta 2-adrenergic 
receptors and alpha 1-adrenergic receptors (Maron & Rocco, 2011).  
Angiotensin converting enzyme inhibitors (ACE-I).  ACE-Is are defined as a 
class of drugs that inhibit the ACE from converting angiotensin I to angiotensin II and is a 
mainstay in ameliorating heart failure morbidity and mortality (Colucci, Gottieg, & Yeon, 
2014).   In a failing myocardium, there is an increase in ACE binding sites.  ACE is a 
vasoconstrictor causing increased blood pressure and myocardial hypertrophy (Colucci, 
Gottieb, & Yeon, 2014).  ACE inhibitors also have a role in blocking the RAAS in HF 
patients. The RAAS is a hormonal cascade that maintains homeostatic control of blood 
pressure by regulating tissue perfusion and extracellular volume. In HF, the RAAS is 
accelerated (Bissessor & White, 2007).  
Angiotensin II receptor blocker (ARB). ARBs are defined as a class of drugs 
that block the binding of angiotensin II to AT1 receptor.  ARBs are used when HF patients 
are not able to tolerate ACE inhibitors (Colucci, Gottieb, & Yeon, 2014).  The Eperenone 
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in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) 
trial and Randomized Aldactone Evaluation Study (RALES) trials showed that ARB add-
on therapy did not reduce all-cause mortality (McMurray et al., 2012).   The ACCF/AHA 
guidelines state that the combination of an ACE inhibitor, ARB, and aldosterone 
antagonist has the potential for harm in patients with HFrEF (Yancy et al., 2013).  
Risk for Readmission Prediction Score (RRPS) 
RRPS is the score generated by the Risk for Readmission Prediction tool utilized at 
the facility where this project was conducted. A systematic review of prediction models 
for hospital readmission risk show they perform poorly (average C-statistic of 0.66) 
(Choudhry et al., 2013).  However, the prediction tool purchased by the facility where this 
project was conducted demonstrates modest discrimination ability during derivation, 
internal and external validation post-recalibration (C-statistics of 0.78) and reasonable 
mode fit during external validation for utility in heterogeneous populations (Choudhry et 
al., 2013).  The discharge risk for readmission prediction model includes 58 independent 
predictors such as demographics, hospital utilization, medications, labs, history and 
physical, procedures, length of stay, and discharge disposition.  In order to create a highly 
predictive model, the quality and accessibility of the data is important.  Patients were 
given a score generated by the prediction model according to their risk stratification: 0-40 
low risk, 41-49 moderate risk, and 60-100 high risk.  
Theoretical Framework 
Roger’s Diffusion of Innovation (DOI) theory provided a theoretical framework 
for the implementation of readmission predictor assessment. A risk for 30-day HF 
readmission model supported innovation and uptake of new care modalities.  Rogers (2003) 
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defined diffusion as “the process by which an innovation is communicated through certain 
channels over time among the members of a social system” (p.35).  Conceptualized ideas 
were innovations communicated through channels over time in a social system (Rogers, 
2003). The ultimate goal of understanding the etiology of 30-day HF readmissions was to 
propose a quality improvement plan for readmission prevention.  The clinical innovation of 
risk for readmission predictors based on evidence has the potential for significant 
organizational improvement. Bucknall (2012) emphasized the importance of the translation 
of knowledge into action and behavior changes. The DOI theory bridged the know-do gap 
between identified trends and the implementation of a prevention plan.  
Elements of Diffusion of Innovation 
 The four elements of Roger’s theory included innovation, communication 
channels, time, and social system.  . 
 Innovation.  Innovation, according to Rogers (2003) was an idea perceived as 
“new”. The adopters must understand the advantages, disadvantages, and consequences of 
the innovation.  Stakeholders of the facility invested in new technology to identify heart 
failure patients that were at high risk for readmission. The goal became to educate the 
adopters on the importance of the new technology. The employees were informed of the 
financial penalty the facility endured due to the reoccurrence of 30-day HF readmissions.  
The employees understood that action needed to be taken to prevent reoccurrence in order 
to avoid future penalties.  
 Communication channels.  Communication channels were the second element of 
the diffusion of innovation process. Rogers (2003) defined communication as the process 
of mutual understanding through information sharing.  Two communication channels were 
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mass media or interpersonal communication (Rogers, 2003).  Rogers (2003) stated that 
interpersonal communication is most effective when strong opinions prevail. To ensure 
the adopters were well informed, town hall meetings were utilized to inform the 
employees of the urgency in addressing the readmission rate.  Committee meetings were 
held monthly to tailor the readmission predictor tool unique to the facility’s needs.  
 Time. Time is the third element of the diffusion of innovation process. There was 
a sense of urgency in creating an action plan for the prevention of readmissions.  The 
proposed timeline for launching the readmission predictor tool was seven months. 
However, 11 months lapsed from time of purchase to the launch.  To ensure that the 
readmission tool was complete, the launch was delayed three months.  
 Social system. The fourth element of the diffusion of innovation process was the 
social system.  Social system, as defined by Rogers (2003), was “a set of interrelated units 
engaged in joint problem solving to accomplish a common goal” (p.23).  The 
organization’s social system consisted of a Chief Medical Officer (CMO), a Chief 
Executive Officer (CEO), a Chief Operating Officer (COO), a Chief Nursing Officer 
(CNO), a Board of Trustees, department heads, unit managers, and staff.  The emphasis of 
the leadership was teamwork.  Ideas were welcomed in this social system. However, due 
to the magnitude of the financial commitment to purchase a risk for readmission tool, the 
decision was made by the CMO, CEO, COO, CNO, and Board of Trustees.  A team of 
informatics technology nurses, case managers, social workers, and nurses executed the 
implementation.  
Innovation-Decision Process 
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According to Rogers (2003), five steps in the innovation-decision process included 
knowledge, persuasion, decision, implementation, and confirmation.  
Knowledge. The first step of the innovation-decision process was knowledge.  
Adopters gathered information about the innovation. Questions asked during the cognitive 
knowledge step seek to answer “what”, “how”, and “why”. The adopters sought 
knowledge on factors the readmission predictor assessment included, how it was to be 
implemented, and the rationale behind the implementation. 
Persuasion. Persuasion was the second step of the innovation-decision process.  
Once knowledge was obtained, adopters form an opinion, favorable or unfavorable.  
Opinions and beliefs about the innovation were affected by peers’ views and the 
uncertainty of the innovation (Rogers, 2003).   The stakeholders were persuaded through 
peer influence to purchase the readmission predictor tool. The stakeholders were in turn 
able to persuade managers and staff that the innovation would be beneficial.  
Decision. The third step was the decision stage when the individual or group chose 
to accept or reject the innovation.  Rogers (2003) described two types of rejection 
including active rejection or passive rejection.  Rogers (2003) suggested that active 
rejection exists when an individual rejects an innovation after trying it.  Further, he 
suggested that passive rejection exists when an individual rejects an innovation without 
consideration of adopting it.   
The decision makers at the organization where this scholarly project was 
implemented chose to accept the innovation despite risks and uncertainty.  The 
administrators were assured that the benefits of the innovation outweighed the risk.   
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Implementation. The implementation phase occurred when the innovation was 
put into practice.  Months of planning went into the implementation phase of the risk for 
readmission predictor tool once the decision to move forward was made. The risk 
assessment tool involved several variables that required input from physicians, nurses, lab, 
case managers, and demographic data. The organization continued to plan for 
implementation but, due to the complexity and barriers, implementation did not occur 
during the scholarly project timeframe.. The author created an alternate readmission risk 
assessment tool in order to assess suspected factors in 30-day HF readmissions based on 
the body of evidence.  
Confirmation. The fifth step in the innovation-decision process was confirmation.  
Adopters looked for support that they made the right decision.  Despite conflicting 
messages, adopters surround themselves with supporters (Rogers, 2003).  The facility 
networked with other facilities that had purchased the same risk for readmission predictor 
tool.  They sought support in their decision and ongoing use.  
Characteristics of Innovation 
DOI theory identified factors that can enhance process of change and indicated 
whether an innovation will be accepted. Rogers’ innovation characteristics included 
observability, relative advantage, compatibility, trialability, and complexity (Rogers, 2003).  
Observability. Observability referred to how visible the innovation is to potential 
adopters. Providers were more apt to accept an innovation if they are able to observe it 
(Rogers, 2003).  The electronic medical record displayed an easily accessible risk for 
readmission score.  However, few staff were aware of its meaning.  Inservices were 
ongoing so staff could observe the utility of readmission risk assessment tools. 
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Relative advantage. Relative advantage referred to the degree to which an 
innovation was perceived to be superior to the current practice. Current practice did not 
have in place a specific plan targeting 30-day HF readmissions. Employees were made 
aware of the importance of implementing robust readmission prevention program in order 
to avoid future financial penalty and meeting the organization’s strategic mission.   
Compatibility. Compatibility referred the degree to which innovation was 
perceived to be consistent with socio-cultural values, previous ideas, or perceived needs 
(Rogers, 2003). The mission of the employees was to focus on superior quality health care 
services and to improve the health of the community in a caring, efficient and financially 
sound manner.  The implementation of a 30-day HF readmission prevention initiative was 
compatible with their mission.   
Trialability. Trialability referred to how much the innovation can be experienced.  
New ideas that can be tried will generally be adopted more quickly (Rogers, 2003).  Rogers 
(2003) pointed out that reinvention often takes place during the trial of innovation.  
Reinvention frequently occurred as planners tailored the assessment to the unique needs of 
the patients in their community.  
Complexity. Complexity was defined according to level of difficulty.  A complex 
innovation is difficult to embrace (Rogers, 2003).  The goal was to make the recommended 
process change user-friendly and easily accessible. However, the creation of the tool was 
complex. Committee meetings, conference calls with the vendor, and data gathering were 
time consuming. The timeline has extended longer than expected. 
Adopters of change 
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In addition to understanding the five stages of DOI and the innovation 
characteristics that led to the successful implementation of a proposed innovation, the 
author needed to identify the individuals likely to accept or reject the innovation.  Rogers 
referred to these individuals as adopters.  Rogers set forth five categories of adopters 
including innovators, early adopters, early majority, late majority, and laggards.  
Innovators. Innovators venturesome and change agents. They are risk takers as 
well as gatekeepers of new innovation (Rogers, 2003). They make up 2.5% of the social 
system (Rogers, 2003). The stakeholders, representing a small group of decision-makers, 
researched readmission prevention models and were willing to take the risk to make the 
investment. 
Early adopters. Early adopters are visionaries.  They are the trendsetters and role 
models.  Early adopters make up 13.5% of the social system. Early adopters set the tone for 
acceptance amongst the social system (Rogers, 2003). Rogers (2003) points out that 
innovators and early adopters are usually well-educated and open to new ideas. 
Early majority. Early majority are the pragmatists. They are conservative, 
prudent, and do not like complexity. This group represents 34% of the social system. 
Late majority. Late majority are skeptical. They are cautious and succumb to peer 
pressure.  Late majority represents 34% of the social system. This group waits until most of 
the social system has accepted the new idea.  
Laggards. Laggards are the last group to accept change.  They prefer the status 
quo and their point of reference is the past. They are suspicious of change. Laggards 
represent 16% of the social system.  This group often waits to see if the change is 
successfully implemented.  
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The innovators of the implementation facility were comprised of a small group of 
decision-makers. The innovators included the CEO, CMO, and CNO and the nurse leader 
for the readmission prevention task force. The early adopters included a team of case 
managers, nurses, and an IT team.  The innovators and early adopters were the driving 
force of the implementation of the new innovation. They were forward thinking and 
progressive and set the tone for acceptance.  The early majority included the case managers 
and staff nurses. The tool was created to be user-friendly in order for acceptance and 
implementation.   Since the launch was recent, it was too early to evaluate the late majority 
or laggard reaction to the implantation. 
In summary, Roger’s diffusion of innovation theory offered a plausible explanation 
for why some innovations are adopted rapidly and others with difficulty, despite strong 
evidence of the potential benefits. The implementation of change involved a complex 
interplay between social systems, communication style, adopter characteristics, and the 
decision-making process.  DOI provided the theoretical framework for the implementation 
of the risk for readmission predictor tool in a rural community hospital.   
 
CHAPTER 3: METHODOLOGY 
Needs Assessment 
The questions explored for this project were: 1) Is there a difference between age 
and 30-day readmissions? 2) Is there a relationship between days until follow up visit and 
30-day readmissions? and 3) Is there a correlation between patients not on the appropriate 
medication regimen and 30-day readmissions?  The implementation facility explored ways 
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to predict and prevent 30-day readmissions in HF patients after being penalized by 
regulatory agencies.   
Despite best efforts, HF readmissions continued to be a problem. The 
stakeholders invested in a prediction readmission model from the electronic health record 
(EHR) provider. However, even with a team meeting weekly with the representatives from 
the EHR provider to tailor the prediction model to the unique needs of the population 
served by the facility, launch of the tool has not occurred.  
Project Design 
In this quantitative study using descriptive statistics, the outcome was to better 
understand the causes of 30-day heart failure readmissions in order to predict and prevent 
their occurrence. Formal presentation of the proposed scholarly project was made in 
January 2015 at the facility in which this study was completed. Organizational institutional 
review committee (IRC) approval was obtained March 4, 12015 (see Appendix A).  
University Medical Center Institutional Review Board (UMCIRB) approval was obtained 
May 7, 2015 (See Appendix B). 
A retrospective chart review was conducted over 6 months following IRB 
approval. Data were collected on charts identified by ICD-9 codes for HF with 
readmissions within 30 days of discharge between January 2013 to March 2015. Data were 
accessed using an encounter number with an individual access code specific to the principal 
investigator. Electronic data was stored in a password-protected document in a password-
protected computer in a locked location. The principal investigator (PI) had the password 
and encryption codes with sole access to the data. The PI did not collect protected health 
information (PHI) identifying data. The electronic file will be shared with the IRC at the 
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facility where the project took place on completion of the project.  The data will then be 
subsequently stored on the encrypted hospital R drive for six years.  
A chart review tool with a code legend was utilized for data collection (see 
Appendix C). The tool consisted of variables including age, gender, tobacco use, Ace 
Inhibitor or ARB, Beta-blockers, ejection fraction, days between discharge and follow up 
visits, and days between discharge and readmission.  Data were not collected on individuals 
greater than 89 years old since this is considered a personal identifier. The data were 
entered into a spreadsheet. There were 52 heart failure readmissions in 2013 and 73 heart 
failure readmissions in 2014; therefore the sample size was estimated to be no greater than 
150 encounters.   
This quality improvement project evaluated possible factors that might predict 
readmissions of high-risk heart failure patients.  
Failure Mode Effects Analysis (FMEA), as defined by the Institute for Healthcare 
Improvement is, “a systematic proactive method for evaluating a process to identify where 
and how it might fail and to assess the relative impact of different failures, in order to 
identify the parts of the process that are in the most need of change” (Institute for 
Healthcare Improvement, 2015). The ultimate goal of FMEA is to redesign systems to 
optimize patient outcomes (Reams, 2011). Latino and Fernandes (2013) stated the 
organization must identify the latent root causes that contribute to 30-day readmissions.  
Latent root causes are the systemic or organization deficiencies that can mislead decision 
makers. Once the root cause analysis (RCA) is done and latent root causes are identified, 
FMEA can be implemented. The identified problem is given a score depending on severity, 
probability, and detectability. The resulting score of these factors is known as the risk 
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priority number (RPN).  A high RPN indicates a high priority problem.  Once a failure 
mode is identified, an individual or team implements action(s). Once the action is complete 
a new RPN is calculated which will determine if there has been improvement (Reams, 
2011).   The results from this quality improvement scholarly project identified potential 
factors of 30-day readmissions heart failure patients and provided focused areas for 
prevention.  
Resources used/cost analysis 
     Resources utilized were the IT department at the study facility. The liaison 
between EHR and the hospital provided the list of HF 30-day readmissions encounter 
numbers for the chart review. Travel and indiscriminate costs totaling $500 were incurred 
with this scholarly project.  A timeline was kept during the duration of the DNP project 
(See Appendix D). 
CHAPTER 4: RESULTS 
One hundred forty-five subjects met 30-day HF readmission criteria, with fifteen 
not meeting inclusion criteria based on advanced age of greater than 89 years of age. The 
final sample (n=130) included 52 males (35.9%) and 78 females (53.8%).  The sample 
ranged in age from 38-89 years (mean [SD], 71.8 [11.8] years) (see Figure 1).  Of the 
sample, 27 (18.6%%) were smokers, 62 (42.8%) were not smokers, and smoking history 
was not documented on 41 (28.3%) (See Table 1).   
Results revealed that 45 (31%) were on an ACE -I, 8 (5.5%) were on an ARB, and 
77 (53.1%) were on neither an ACE-I nor ARB.  Those on beta-blockers were: Bisprolol 4 
(2.8%), Carvedilol 50 (34.5%), Metoprolol 47 (32.4%) and none of the above 29 (20%).  
Cross tabulation revealed that 45 (34.6%) were on both ACE-I or ARB and a Beta-
30-DAY HEART FAILURE READMISSIONS 
 
32 
Blocker. Cross tabulation revealed that 21 (16%) were not on any medication including 
and ACE-I, ARB, or beta-blocker (see Table 2). 
 Ejection fraction (EF) ranged from 8-70% (M 42.2, SD16).  Frequency studies 
revealed the most frequent EF was 55% (32, 22.1%), then 30% (17, 11.7%), and next 60% 
(15, 10.3%). The results showed 8 (6.2%) had an EF ≥ 50% with no echocardiogram 
abnormalities.  Ejection fractions ≥ 50% with abnormalities was 53 (40.7%).  Noted 
abnormalities included pulmonary hypertension, E/A reversal, hypokinesis, impaired 
ventricular relaxation, and aortic stenosis.  Ejection fractions ≤ 50% were 69 (53.1%).  
Days between discharge and follow up visit ranged from 0-28 days, (M 8.5, SD 
5.95).  Frequency studies revealed the most frequent days between discharge and follow 
up visit was 7 days (28, 19.3%), then 2 days (18, 12.4%), and next 10 days (12, 8.3%).   
Days between discharge and readmission ranged from 0-30, (M 14.3, SD 8.3).  
Frequency studies revealed the most frequent days between discharge and readmission 
was 6 days (12, 8.3%), then 5 days (11, 7.6%), and next 12 days (8, 5.5%).   
Risk for readmission scores could not be obtained due to the delay in launch of the 
program at the facility. Relationship between days to follow up and days to readmission 
showed that 36 (27.7%) were readmitted before follow up visit and 89 (68.5) were 
readmitted after follow up visit, and 5 (3.8%) were readmitted the same day as their follow 
up visit. Results showed an average of 5.42 days existed before readmission for those 
readmitted before follow up visits and 10.7 days before readmission for those readmitted 
after follow up visit.  Pearson’s correlation showed there was a weak, negative correlation 
not statistically significant between the two variables, r = -.29, n = 130, p > 0.05 (see 
Table 3). Descriptive statistics showed there was an average of 14.85 days to readmission 
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for those <  70 years of age and 14.01 days to readmission for those ≥ 70 years of age. In 
addition, data show that there was an average of 13 days between discharge and 
readmission for those on both an ACE-I or ARB and a beta blocker and those on neither 
(See Table 4). 
 
Failure Mode Effects Analysis 
The first step for performing a FMEA analysis is to identify the process to be 
addressed and create a flow chart.  All potential failure modes, causes, and effects 
associated with the process are identified.  A Risk Priority Number (RPN) is then 
calculated including severity, occurrence, and detection of the problem. Once the RPN is 
calculated, actions are identified to address the failure modes. Next, the actions are re-
assessed to evaluate their impact and a new RPN is calculated.  The new RPN will 
determine if further action needs to be taken (Reams, 2011). The ultimate goal of FMEA 
is to redesign systems to optimize patient outcomes (Reams, 2011). The RPN for 30-day 
heart failure readmission is 10 (severity) x 10 (occurrence) x 10 (detection) =1000.  The 
severity score is a 10 due to significant financial penalties.  The occurrence score is a 10 
since the readmission rate of the facility is higher than the national average. The detection 
score is a 10 since 30-day HF readmissions are difficult to detect. The high score reiterates 
that 30-day heart failure readmissions are a priority that needs attention in order to 
improve patient outcomes. Root causes of 30-day heart failure readmissions include 
timely follow up visits, discharge medication regimen, transportation barriers, insurance 
barriers, and co-morbidities, to mention a few. Strategies that address the identified root 
causes can then be implemented. FMEA involves several steps with an interprofessional 
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team that can take months.  It is beyond the scope of this DNP project and outside the 
timeline to conduct a formal FMEA analysis. 
CHAPTER 5: DISCUSSION 
Significance 
This aim of this DNP project was to determine if 30-day heart failure readmissions 
could be prevented or predicted by identifying patterns and trends.  The author sought to 
answer three questions: 1) Is there a relationship between age and 30-day heart failure 
readmissions? 2) Is there a relationship between days to follow-up and 30-day heart failure 
readmissions? and 3) Is there a difference between patients not on appropriate medication 
regimen and 30-day heart failure readmissions?   The empirical findings from the chart 
review of 130 patient encounters showed no relationship between age and 30-day 
readmissions.  Second, the data suggested there was no relationship between days to 
follow up and 30-day readmissions. In fact, 68.5% of heart failure readmissions occurred 
after the scheduled follow-up visit within the 30-day window post discharge. Last, 
findings suggested there was no relationship between medication regimen and 
readmission. A relevant finding was that patients were on medication regimens that did 
not align with the evidence-based guidelines.    
Implications 
The implications of the findings suggested that 30-day heart failure readmissions 
are multifactorial.  Physical, social, and psychosocial issues were contributory factors 
confounding the ability to predict and prevent their occurrence.  In addition, co-
morbidities of heart failure patients clouded the predictability of readmission. The 
literature revealed that one prediction model for heart failure readmission does not fit all. 
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In addition, the evidence-based guidelines do not fit all heart failure patients regardless of 
age. 
 
Recommendations 
The scale of heart failure 30-day readmissions is extensive and multifaceted at 
both small and large facilities.  In order to further address the issue of 30-day heart failure 
readmissions, the following recommendations were made.  A formal FMEA analysis 
would identify the root causes specific to the facility and enable the creation of strategies 
for prevention A discharge nurse specific to heart failure patients was recommended to 
ensure adequate discharge instruction, schedule the follow up appointment within seven 
days, and assess accessibility and affordability of discharge medication regimen may 
ameliorate some of the psychosocial and socioeconomic factors of readmission. This 
author recommended an outpatient heart failure clinic with an appointed APRN to 
evaluate and manage the patients with heart failure post discharge within seven days and 
continue to follow them weekly and as needed until the 30-day post discharge window 
passes. In addition, palliative care or hospice for those who have recurrent advanced heart 
failure should be considered as best practice.  Further quality improvement cycles were 
recommended to examine the facility’s readmission predictor tool in identifying high-risk 
patients for readmission. 
Limitations of the project 
The initial goal of this project was to analyze the implementation of an initiative 
using a risk for readmission score in order to stratify high-risk patients for 30-day 
readmissions.  Due to a delay in the institution’s launch date, this DNP project was 
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amended to enable evaluation of 30-day heart failure readmissions using a chart 
review tool created by the author. The chart review tool measured eight variables 
based on application of best evidence for heart failure management, which was 
substantially less detailed than the planned prediction tool, but captured current 
CMS heart failure performance measures and evidence-based recommendations.  
Another limitation was that data were limited within the encounters to 
identify if patients had taken the medications as prescribed.  In addition, data were 
limited with regards to the ability to follow-up in the recommended window with 
the patient’s healthcare provider.  
CHAPTER 6: CONCLUSIONS 
Prediction and prevention of heart failure readmissions is complex.  This DNP 
project contributes to the body of knowledge by reiterating the importance of strategies 
targeted at the root causes of heart failure readmissions.  The data suggested that causes of 
30-day readmissions were not correlated with age, time of follow up visit, or a specific 
medication regimen.  
Dissemination of the project included a formal presentation to DNP faculty and 
colleagues, presentation to the readmission team at the implementation facility, and 
journal submission to Clinical Scholars Review.  The facility is exploring an outpatient 
clinic for recently discharged patients as recommended. As suspected at the onset, 
potential strong predictors for 30-day readmission including physical, social, or 
psychosocial factors need to be addressed in order to predict and prevent 30-day heart 
failure readmissions. A formal FMEA analysis will assist facilities in identifying causes of 
30-day heart failure readmissions unique to their community.  APRNs could play a pivotal 
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role in providing follow up care for recently discharged heart failure patients in both small 
and large facilities. The findings of this scholarly project are generalizable to rural 
community hospitals.  
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Table 1  
Gender, Smoker Frequency Data  
________________________________________________________________________                                                                                            
 
Variable  Encounters (n=130) 
    N              % 
  
Sex  
  Male     52              40% 
  Female    78              60% 
Smoker  
  Yes    27               18.6% 
  No     62               42.8% 
  Not Documented    41               28.3% 
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Table 2 
 
Medication Regimens 
____________________________________________________________________________________ 
 
Medication ACE-I ARB Neither Total 
     
Bisprolol 0 1 3 4 
Carvedilol 19 3 28 50 
Metoprolol 20 2 25 47 
No BB 6 2 21 29 
Total 45 8 77 130 
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Table 3 
 
Pearson’s Correlation between Age and 30-Day HF Readmissions 
________________________________________________________________________ 
 
  Age  Days to Readmission 
   
Age                         Pearson’s 
                                Correlation 
                                Sig (2 tailed) 
                                N 
1 
 
 
130 
-0.29 
 
.740 
130 
Days to Readmit     Pearson’s 
                                Correlation 
                                Sig (2 tailed) 
                                N 
-.029 
 
.740 
 130 
1 
 
 
130 
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Table 4 
 
Cross Tabulation between Medication Regimen and 30-Day HF Readmissions 
________________________________________________________________________ 
 
Medications N, % Days between discharge 
and readmission 
   
Both ACE-I/ARB and BB 45, 34.6% 13.53 
Neither 21,16% 13.38 
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Figure 1 
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Appendix B 
 
EAST  CAROLINA  UNIVERSITY 
University & Medical Center Institutional Review Board Office  
4N-70 Brody Medical Sciences Building· Mail Stop 682 
600 Moye Boulevard · Greenville, NC 27834 
Office 252-744-2914 · Fax 252-744-2284 · www.ecu.edu/irb 
   
 
Notification of Exempt Certification 
 
From: Biomedical IRB  
To: Susan Gray  
CC:  Candace Harrington  
Date: 5/7/2015  
Re: UMCIRB 14-002137  Evaluation of Prediction Tool for Heart Failure Readmissions 
 
 
I am pleased to inform you that your research submission has been certified as exempt on 5/7/2015. This 
study is eligible for Exempt Certification under category #4. 
  
 
It is your responsibility to ensure that this research is conducted in the manner reported in your application 
and/or protocol, as well as being consistent with the ethical principles of the Belmont Report and your 
profession. 
This research study does not require any additional interaction with the UMCIRB unless there are proposed 
changes to this study. Any change, prior to implementing that change, must be submitted to the UMCIRB 
for review and approval. The UMCIRB will determine if the change impacts the eligibility of the research 
for exempt status. If more substantive review is required, you will be notified within five business days. 
The UMCIRB office will hold your exemption application for a period of five years from the date of this 
letter. If you wish to continue this protocol beyond this period, you will need to submit an Exemption 
Certification request at least 30 days before the end of the five year period. 
The Chairperson (or designee) does not have a potential for conflict of interest on this study. 
 
 
  
IRB00000705 East Carolina U IRB #1 (Biomedical) IORG0000418 
IRB00003781 East Carolina U IRB #2 (Behavioral/SS) IORG0000418 
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Appendix C 
	  	  
Ace/Arb	   Beta	  Blocker	   Smoker	   EF	  %	  
Age	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
if	  <	  89	  yrs	  
old	  
	  
Gender	  
#	  of	  Days	  
between	  
Discharge	  
and	  Follow	  
up	  visit	  
#	  of	  Days	  
between	  
discharge	  and	  
readmission	  
Risk	  for	  Readmission	  
Prediction	  Score	  if	  	  
	  	  	  	  	  	  	  available	  
1	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
2	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
3	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
4	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
5	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
6	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
7	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
8	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
9	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
10	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
11	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
12	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
13	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
14	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
15	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
16	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
17	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
18	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
19	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
20	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
21	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
22	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
23	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
24	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
.	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
130	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
 
Code Legend 
Ace/ARB    Smoker 
1. Ace Inhibitor   1.    Yes 
2. ARB    2.    No 
3. None of the Above   3.    Not documented 
Beta Blocker    Gender 
1. Bisoprolol    1.    Male 
2. Carvediolol    2.    Female 
3. Metoprolol 
4. None of the above  
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Appendix D 
Timeline 
1/26/15  DNP power point presentation 
2/02/15  Initial meeting with Jill Steward, Nursing Research Council 
2/03/15  Established secure R drive with IT representative 
2/11/15  Formal presentation to Nursing Research Council 
3/04/15  Letter of approval obtained from Institutional Review Committee of   NHCS 
3/13/15  IRB application submitted  
3/24/15  IRB revisions complete 
5/07/15  ECU IRB Approval 
6/20/15  Chart Review Data Collection Completed 
9/09/15                  Presentation of DNP project to committee with approval  
9/16/15                  Presentation of DNP at intensives 
12/1/15                  Final Paper Approval 
12/1/15                  Journal Submission  
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Appendix E 
 
